poor metabolizer

poor metabolizer

Pharmacology A person who metabolizes a probe drug–the rate of which is related to the metabolizing cytochrome P-450 enzyme–slower than others; a person can be a PM of one probe drug, and an extensive metabolizer of another. See Probe drug. Cf Extensive metabolizer.
References in periodicals archive ?
Even when handed information on whether each clopidogrel-treated patient was a poor metabolizer of the drug, treating physicians usually did not switch them to a different antiplatelet drug, ticagrelor, that would be fully effective despite the patient's reduced-metabolizer status.
C's presentation, as well as information from the CPIC guidelines, we expect that she might experience substantial adverse effects from most selective serotonin reuptake inhibitors and tricycle antidepressants because of her intermediate metabolizer status for CYP2D6 and poor metabolizer status for CYP2C19.
In fact, if she were poor metabolizer due to CYP2D6 polymorphism, the potential accumulation of the drug would have surely resulted in a more profound blood pressure reduction.
Polymorphisms of population in pharmacogenetics are divided into the phenotypes as poor metabolizer (PM), intermediate metabolizer (IM), Extensive Metabolizer (EM), and ultra-rapid metabolizer (UM) (7,8).
Using an established consensus-building method that included multiple rounds of surveying, more than 90 percent of participating experts agreed to replace those descriptions with a single term, poor metabolizer.
The activity of CYP2D6 is largely determined by genetic variability and common sequence variants exist in human populations that lead to poor metabolizer (PM) phenotypes [72].
For example, patients carrying 2 nonfunctional alleles that give rise to CYP2D6 poor metabolizer status derive little or no pain relief from codeine and tramadol.
The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
When patients undergo pharmacogenetic testing, they are categorized into one of four phenotypes: ultra-rapid metabolizer (UM), extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM).
The traditional assignment of phenotype is as follows: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM), and ultrarapid metabolizer (UM).
It has been shown that about 3% of Caucasians express the poor metabolizer phenotypes S-mephenytoin, however literature review in this regards shows slight differences.